Published in final edited form as:

Mov Disord. 2011 August 15; 26(10): 1875–1880. doi:10.1002/mds.23746.

Mood and Cognition in Leucine-rich Repeat Kinase 2 G2019S Parkinson's Disease

Vicki Shanker, MD¹, Mark Groves, MD¹, Gary Heiman, PhD², Christina Palmese, PhD¹, Rachel Saunders-Pullman, MD, MPH¹, Laurie Ozelius, PhD³, Deborah Raymond, MS¹, and Susan Bressman, MD¹

¹Beth Israel Medical Center, New York, USA

²Rutgers University, Piscataway, USA

³Mount Sinai Medical Center, New York, USA

Abstract

INTRODUCTION—The behavioral and cognitive features of the leucine-rich repeat kinase G2019S mutation in Parkinson's disease in the Ashkenazi Jewish population are not well described; therefore we sought to more systematically characterize these features using a semi-structured psychiatric interview and neuropsychological testing.

Please address proofs to: Vicki Shanker, MD, Beth Israel Medical Center, 10 Union Square East, Suite 5H, New York, NY 10003, vshanker@chpnet.org, (212) 844-6902 (telephone), (212) 844-8461 (fax).

Financial Disclosures/Conflicts of Interest: The authors have nothing to disclose.

Author's roles:

1. Research project: A. Conception, B. Organization, C. Execution
2. Statistical analysis: A. Design, B. Execution, C. Review and Critique
3. Manuscript: A. Writing of the first draft, B. Review and Critique

Vicki Shanker:	1A, 1B, 1C, 2A, 2C, 3A, 3B
Mark Groves:	1C, 2B, 2C, 3A, 3B
Gary Heiman	2A, 2B, 2C, 3B
Rachel Saunders-Pullman	1C, 3B
Laurie Ozelius	1A, 1C, 3B
Christina Palmese	1A, 1B, 3B
Deborah Raymond	1C
Susan Bressman	1A, 1B, 1C, 2A, 3B

Financial disclosures: Dr. Shanker received consulting fees from Teva Neuroscience. Dr. Groves has received consulting fees from the CHDI Foundation. Dr. Saunders-Pullman receives research support from the Marclad Foundation and the Michael J. Fox Foundation. She was funded by the NIH/NINDS K-23-NS047256 (PI), The Thomas Hartman Foundation for Parkinson's Research and the Bachmann-Strauss Dystonia and Parkinson Foundation during the time of the research. Dr. Ozelius has grants from the Bachmann-Strauss Dystonia and Parkinson Foundation, The Dystonia Medical Research Foundation and NIH NS046340, NS058949, RR026123. She is a current member of the scientific advisory boards of the National Spasmodic Dysphonia Association and the Benign Essential Blepharospasm Research Foundation and a past member of the scientific advisory boards of the Bachmann-Strauss Dystonia and Parkinson Foundation and The Dystonia Medical Research Foundation. Dr. Ozelius receives royalty payments from Athena Diagnostics related to a patent. Athena has supported one Grand Rounds given by Dr. Ozelius. Dr. Bressman is a member of the scientific advisory boards of the Dystonia Medical Research Foundation and the Michael J. Fox Foundation. She receives research support from the National Institutes of Health (NIH) and the Michael J. Fox Foundation. Dr. Palmese and Dr. Raymond have nothing to disclose.

METHODS—Twenty-one Ashkenazi Jewish patients having the leucine-rich repeat kinase G2019S mutation were compared with age, sex and gender matched Ashkenazi Jewish Parkinson's disease patients without mutations.

RESULTS—While overall rates of affective disorders were not greater in mutation carriers, the carriers exhibited a six-fold increased risk of pre-morbid affective disorders (OR 6.0, $p=0.10$) as determined by the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders–IV. Of interest, we identified two leucine-rich repeat kinase carriers with bipolar disorder; no mutation negative subjects had this diagnosis. Performance on the Hopkins Verbal Learning Test- Revised, Judgment of Line Orientation, and Frontal Assessment Battery was consistent with previous reports and did not differ between groups.

DISCUSSION—Study findings suggest a possible association between pre-morbid mood disorders and leucine-rich repeat kinase Parkinson's disease warranting further evaluation.

Keywords

Parkinson's disease; LRRK2; Mood; Depression; Cognition

INTRODUCTION

Parkinson's disease is the second most common neurodegenerative disorder¹ and its diagnostic criteria include the hallmark motor signs of bradykinesia, rest tremor, rigidity and postural instability². In practice, the clinical presentation and course of the disease is heterogeneous with variability in onset, progression, and severity of motor and non-motor symptoms. The basis for this variation in Parkinson's disease phenotype is unknown but thought to be due to environmental and genetic factors^{3–7}. One of these genetic factors is the leucine-rich repeat kinase 2 gene at the PARK8 locus^{8, 9}. At least eight pathogenic *LRRK2* mutations have been identified^{10, 11} and the G2019S mutation is common in certain PD populations, including Ashkenazi Jews; 10–18% of unselected Ashkenazi PD patients and 30% of those with a PD family history are reported to harbor the mutation^{12–14}.

Studies on the clinical expression of G2019S and whether it differs from idiopathic PD are conflicting. Several early studies suggested LRRK2 PD is indistinguishable from sporadic or idiopathic PD^{15, 16}. An analysis of a large combined multinational cohort, however, found that patients with LRRK2 mutations had a more benign course with a lower rate of falls, slower progression, less cognitive decline and less olfaction loss¹⁷. Other studies have identified a more severe disease course with higher UPDRS scores, more dyskinesias, higher dosages of dopaminergic medication, a greater likelihood of the postural instability and gait difficulty phenotype, and greater cognitive impairment^{18–21}.

The behavioral aspects of LRRK2 are even less well established. One Italian study¹⁸ found a high frequency of depression, anxiety and irritability in LRRK2 carriers while another study²² did not find higher rates of depressive symptoms in carriers than non-carriers. In a small single family study, unaffected carriers had similar rates of depression as measured on the Beck depression inventory- second edition (BDI-2) as non-carriers²³. All of these studies assessed current, rather than lifetime, psychiatric symptoms.

In order to more fully characterize the psychiatric and cognitive features associated with *LRRK2* PD, we evaluated cognitive function and lifetime risk for mood disorders in unrelated and independently ascertained Ashkenazi Jewish PD patients with the G2019S mutation.

METHODS

Patient Population

Two hundred twenty-seven unrelated, Ashkenazi Jewish (AJ) Parkinson's disease patients were consecutively screened in the outpatient setting of the Department of Neurology at Beth Israel Medical Center in New York City. All participants were evaluated by movement disorder specialists blinded to genotype and were selected after meeting stringent diagnostic criteria for idiopathic Parkinson's disease²⁴. Ancestry was determined by self-description. Most patients had four Ashkenazi Jewish grandparents. However, five patients were 50% AJ and 50% Non-Jewish. Two additional patients had AJ heritage only from a maternal grandparent. Patients completed questionnaires detailing medical, psychiatric, and social history. Family pedigrees were constructed and patients were asked to detail family medical and psychiatric history. The Unified Parkinson's Disease Rating Scale (UPDRS) and Hoehn and Yahr scale were completed by a movement disorder specialist blinded to genotype. Peripheral blood or 'swish and spit' samples for DNA was obtained with written informed consent after clinical examination was completed.

Forty-two patients were identified as LRRK2 G2019S mutation carriers. Two were deceased, three were lost to follow-up, and six refused further testing. Thirty-one mutation positive patients agreed to complete further neuropsychiatric and cognitive testing; of these, twenty-six completed both; three refused the structured psychiatric interview and two failed to complete neuropsychological testing. Matching every patient with the LRRK2 G2019S mutation to an AJ non-mutation carrier was performed by an unblinded research associate using criteria of current age, sex, disease duration from symptom onset, and age of symptom onset.

Of the thirty-one mutation positive patients, three were not included because they did not have a match: one because of long disease duration (28 years), the second because of an early age of onset (26 years old), and the third because of late age of onset and gender (83 year-old man). Prior to analysis, it was predetermined that controls must complete both neuropsychiatric and cognitive testing for paired analyses. Of the 28 controls identified, all initially agreed to participate in the study. One control died during the study. Six controls did not complete cognitive testing. Thus, twenty-one carrier-control pairs were subsequently analyzed.

Molecular Methods

DNA was extracted from white blood or buccal cells using the Purgene procedure (Gentra Systems Inc, Minneapolis, MN) and the G2019S mutation in the LRRK2 gene was genotyped using a Taqman assay (rs34637584) according to manufacturer's instructions (Applied Biosystems, Foster City CA).

Clinical Testing

Cognitive testing—A research associate trained in the administration of all study measures conducted a 30-minute testing session with each participant. Testing included the Mini-Mental State Exam, the Hopkins Verbal Learning Test (Form 1; HVLT-R), Judgment of Line Orientation test (Form V; JLO), and the Frontal Assessment Battery (FAB). In addition, patients completed the Beck Anxiety (BAI) and Beck Depression Inventories (BDI-2) at this session.

Psychiatric interview—Patients were asked to participate in a phone interview with a psychiatrist who administered the mood disorders module of the SCID: Structured Clinical Interview for the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders–IV).

Blinded to genotype, the psychiatrist assessed each participant for lifetime history of DSM-IV mood disorders, including: Major Depressive Disorder (MDD), Dysthymic Disorder, Depressive Disorder Not Otherwise Specified, Mood Disorder secondary to a general medical condition, and Bipolar Disorder.

Four categories of lifetime prevalence of mood disorders were included: (1) any mood disorder, (2) any major depressive disorder (MDD) (defined as single episode or recurrent MDD), (3) recurrent MDD (defined as having more than one episode of depression), and (4) bipolar disorder. We analyzed recurrent MDD separately because evidence suggests it is more familial²⁵. If a patient reported a mood episode, age of onset was recorded. Premorbid psychiatric disorder was defined as onset at least five years prior to PD motor onset. Comorbid psychiatric disorder was defined as onset less than five years prior to PD motor onset, as the prodromal syndrome of PD is generally estimated to be 4–6 years in duration^{26–30}.

Statistical Methods

Demographic data for the mutation positive and negative individuals were compared using chi-square and ANOVA analyses. Analyses of SCID categorical mood disorders were carried out with conditional logistic regression whereas analyses for continuous outcomes for cognitive variables were carried out with clustered random-effects generalized least squares regression models. For time event variables, a Cox Proportional Hazards stratified by matching variable, was utilized. Time to premorbid mood disorder onset was defined as the number of years until mood disorder onset (if onset occurred at least five years prior to PD onset). Observations were censored on the last clinic visit if subjects did not have onset of any mood disorder by the time of the interview. Statistical analyses were performed using STATA statistical software.

RESULTS

Twenty-one matched pairs were analyzed. Demographic characteristics are presented in Table 1. Conditional logistic regression showed that duration, gender, age at onset, and highest degree of education were not associated with gene status.

Results of the cognitive tests are shown in Table 2. Both groups performed well above the usual cut-offs for dementia on the Mini-Mental Status Exam (MMSE). Mean MMSE scores were 29.2 for LRRK2 carriers and 28.7 for non-carriers. Performance on trials 1–3 and delayed recall of the HVLT-R, JLO, and FAB showed no statistically significant differences between carriers and non-carriers on these measures (Table 2). There were also no statistical significant differences between group means on BAI and BDI-2.

Results of lifetime and premorbid risk for mood disorders are shown in Table 3. Of note, two patients were diagnosed with bipolar disorder using the SCID interview; both were LRRK2 gene carriers. Therefore, bipolar disorder was not included as a separate diagnostic category, but was included as part of any mood disorder. There was a statistical trend ($p=.10$) for LRRK2+ patients to have a higher risk of premorbid any mood disorder ($OR=6.0$). Other sub-analyses of the SCID data did not differ significantly by gene status (Table 3) but tended to be higher for pre-morbid risk than lifetime.

DISCUSSION

Our objective was to characterize the cognitive and psychiatric features of LRRK2 G2019S mutation carriers and broaden the definition of the LRRK2 clinical phenotype to incorporate non-motor features. While lifetime affective disorders overall were not increased in

mutation carriers versus non-carriers, there was a trend for a greater risk of pre-morbid mood disorders in LRRK2 positive PD patients compared to gene negative patients. This suggests a possible association between pre-morbid mood disorders and LRRK2 Parkinson's disease.

Depression may be a risk factor for PD; epidemiologic studies indicate that depressed patients have a 2–3 times higher risk of developing PD^{31, 32}. Additionally, a large population-based historical cohort study of first degree relatives (FDR) of PD patients found an increased rate of depression in the FDR of PD patients, regardless of the patients' individual psychiatric histories.^{33, 34} These studies suggest a shared genetic susceptibility to depression and PD.

The literature on mood disorders in LRRK2 PD is sparse; most reports assess the presence of mood disorders from medical records or scales that measure current psychiatric symptoms, if at all. Table 4 summarizes important previous studies that used specific measures to assess the cognitive and/or psychiatric features of LRRK2 positive G2019S PD.

A putative genetic effect could be expressed at any age; individuals may not have current psychiatric symptoms despite a significant history of depression. Additionally, while some studies use symptom scales as a proxy for diagnosis, "true" diagnosis requires psychiatric interview. Thus, the SCID provides two advantages: (1) assessment of lifetime history and (2) full diagnosis of psychiatric disorders. In addition the SCID better detects depression and anxiety symptoms not detected on the BDI-2 and BAI in our patients. We detected a trend for a greater risk of pre-morbid mood disorders in LRRK2 positive PD patients compared to patients without mutations. Determination of whether this trend highlights a true finding requires further study with a larger sample size, which is ongoing.

The complex relationships between psychiatric disorders (pre-morbid, prodromal and co-morbid) and PD are not yet well understood. Mood disorders may be a phenotypic expression of the LRRK2 G2019S gene expression or, in contrast, mood disorder susceptibility genes may modify LRRK2 mutation penetrance. Either relationship would have profound implications for PD screening and treatment. Aside from depression, we report two patients who developed bipolar disorder. There were no bipolar patients in the matched non-carrier PD group. To our knowledge, this is the first report suggesting that there may be an association between bipolar disorder and the LRRK2 gene. Further study is necessary to explore this possibility as this observation could be solely due to chance.

There are several shortcomings of the SCID. This diagnostic interview is not used commonly in the Parkinson's literature to assess mood disorders; the interview is long and time consuming. Retrospective recollection of mood disorders could be biased by current mood state, among many other factors. The SCID is also interviewer dependent. In our study all interviews were conducted by a single experienced psychiatrist, blinded to genotype, in an attempt to eliminate variability between raters.

There were no significant differences in performance by gene status on the FAB, HVLt-R, and JLO. Our patient population scored within normal range on the MMSE. The cognitive profile detected in this study is consistent with previous literature in Parkinson's disease^{35, 36}. While the MMSE results were in the normal range, MMSE may be a poor screen for the subcortical dementia syndrome more commonly seen in Parkinson's disease^{37–40}. This finding parallels the results of a recent study of early onset LRRK2 PD patients by Alcalay et al. in which their sample had a mean MMSE score of 29.2⁴¹. At the time of study design, the MOCA (Montreal Cognitive Assessment) was not widely used or tested. Future studies may benefit by utilizing screens that are more sensitive to the cognitive deficits associated with Parkinson's disease. Due to time restrictions, the battery of

tests was limited such that examinees could complete testing in 30 minutes. A more extensive battery of tests may have detected other deficits.

Despite our small sample size, this study is one of the largest to date to specifically address the psychiatric and cognitive phenotype of LRRK2 PD. These data will be further expanded in upcoming years in a multi-center effort to better characterize the features of LRRK2 PD.

Acknowledgments

We thank the Parkinson's Study Group, National Parkinson's Foundation and the Michael J. Fox Foundation for their financial support on this project. The authors would like to acknowledge Monica Sethi, Paul Soto, and Jeannie Soto-Valencia for their work on this project.

References

1. Nussbaum R, Ellis C. Alzheimer's disease and Parkinson's disease. *N Engl J Med*. 2003; 348(14): 1356–1364. [PubMed: 12672864]
2. Samii A, Nutt J, Ransom B. Parkinson's disease. *Lancet*. 2004; 363(9423):1783–1793. [PubMed: 15172778]
3. Gasser T. Genetics of Parkinson's disease. *Curr Opin Neurol*. 2005; 18(4):363–369. [PubMed: 16003110]
4. Tan E, Skipper L. Pathogenic mutations in Parkinson disease. *Hum Mutat*. 2007; 28(7):641–653. [PubMed: 17385668]
5. Dick F, De Palma G, Ahmadi A, et al. Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study. *Occup Environ Med*. 2007; 64(10):666–672. [PubMed: 17332139]
6. De Michele G, Filla A, Volpe G, et al. Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. *Mov Disord*. 1996; 11(1):17–23. [PubMed: 8771062]
7. Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. *Acta Neurol Scand*. 2002; 105(2): 77–82. [PubMed: 11903115]
8. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13. 1. *Ann Neurol*. 2002; 51(3):296–301. [PubMed: 11891824]
9. Paisán-Ruiz C, Jain S, Evans E, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron*. 2004; 44(4):595–600. [PubMed: 15541308]
10. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. *Hum Mol Genet*. 2009; 18(R1):R48–59. [PubMed: 19297401]
11. Simón-Sánchez J, Schulte C, Bras J, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. *Nat Genet*. 2009; 41(12):1308–1312. [PubMed: 19915575]
12. Ozelius L, Senthil G, Saunders-Pullman R, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. *N Engl J Med*. 2006; 354(4):424–425. [PubMed: 16436782]
13. Clark L, Wang Y, Karlins E, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. *Neurology*. 2006; 67(10):1786–1791. [PubMed: 17050822]
14. Orr-Urtreger A, Shifrin C, Rozovski U, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? *Neurology*. 2007; 69(16):1595–1602. [PubMed: 17938369]
15. Adams J, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. *Brain*. 2005; 128(Pt 12): 2777–2785. [PubMed: 16081470]
16. Ross O, Toft M, Whittle A, et al. Lrrk2 and Lewy body disease. *Ann Neurol*. 2006; 59(2):388–393. [PubMed: 16437559]

17. Healy D, Falchi M, O'Sullivan S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. *Lancet Neurol.* 2008; 7(7):583–590. [PubMed: 18539534]
18. Goldwurm S, Zini M, Di Fonzo A, et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. *Parkinsonism Relat Disord.* 2006; 12(7):410–419. [PubMed: 16750929]
19. Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. *Ann Neurol.* 2005; 58(5):784–787. [PubMed: 16240353]
20. Nishioka K, Kefi M, Jasinska-Myga B, et al. A comparative study of LRRK2, PINK1 and genetically undefined familial Parkinson's disease. *J Neurol Neurosurg Psychiatry.* 2010; 81(4):391–395. [PubMed: 19726410]
21. Alcalay R, Mejia-Santana H, Tang M, et al. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. *Arch Neurol.* 2009; 66(12):1517–1522. [PubMed: 20008657]
22. Pankratz N, Marder K, Halter C, et al. Clinical correlates of depressive symptoms in familial Parkinson's disease. *Mov Disord.* 2008; 23(15):2216–2223. [PubMed: 18785635]
23. Lohmann E, Leclerc L, De Anna F, et al. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. *Parkinsonism Relat Disord.* 2009; 15(4):273–276. [PubMed: 18718805]
24. Gelb D, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. *Arch Neurol.* 1999; 56(1):33–39. [PubMed: 9923759]
25. Maher BS, Marazita ML, Zubenko WN, et al. Genetic segregation analysis of recurrent, early-onset major depression: evidence for single major locus transmission. *Am J Med Genet.* 2002; 114(2):214–221. [PubMed: 11857584]
26. Marek K, Innis R, van Dyck C, et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. *Neurology.* 2001; 57(11):2089–2094. [PubMed: 11739831]
27. Morrish P, Rakshi J, Bailey D, Sawle G, Brooks D. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. *J Neurol Neurosurg Psychiatry.* 1998; 64(3):314–319. [PubMed: 9527140]
28. Fearnley J, Lees A. Ageing and Parkinson's disease: substantia nigra regional selectivity. *Brain.* 1991; 114 (Pt 5):2283–2301. [PubMed: 1933245]
29. Goner E, van't Hof M, Berger H, van Weel C, Horstink M. Symptoms and duration of the prodromal phase in Parkinson's disease. *Mov Disord.* 1997; 12(6):871–876. [PubMed: 9399209]
30. Braak H, Del Tredici K, Rüb U, de Vos R, Jansen Steur E, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging.* 2003; 24(2):197–211. [PubMed: 12498954]
31. Schuurman A, van den Akker M, Ensink K, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. *Neurology.* 2002; 58(10):1501–1504. [PubMed: 12034786]
32. Shiba M, Bower J, Maraganore D, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. *Mov Disord.* 2000; 15(4):669–677. [PubMed: 10928577]
33. Arabia G, Grossardt B, Geda Y, et al. Increased risk of depressive and anxiety disorders in relatives of patients with Parkinson disease. *Arch Gen Psychiatry.* 2007; 64(12):1385–1392. [PubMed: 18056546]
34. Rocca W, Peterson B, McDonnell S, et al. The Mayo Clinic family study of Parkinson's disease: study design, instruments, and sample characteristics. *Neuroepidemiology.* 2005; 24(3):151–167. [PubMed: 15677876]
35. McKinlay A, Grace R, Dalrymple-Alford J, Roger D. Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease. *Dement Geriatr Cogn Disord.* 2009; 28(2):121–129. [PubMed: 19690414]
36. McKinlay A, Grace R, Dalrymple-Alford J, Roger D. Characteristics of executive function impairment in Parkinson's disease patients without dementia. *J Int Neuropsychol Soc.* 2010; 16(2):268–277. [PubMed: 20003582]

37. Gill D, Freshman A, Blender J, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. *Mov Disord.* 2008; 23(7):1043–1046. [PubMed: 18381646]
38. Mamikonyan E, Moberg P, Siderowf A, et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. *Parkinsonism Relat Disord.* 2009; 15(3):226–231. [PubMed: 18595765]
39. Nazem S, Siderowf A, Duda J, et al. Montreal cognitive assessment performance in patients with Parkinson's disease with "normal" global cognition according to mini-mental state examination score. *J Am Geriatr Soc.* 2009; 57(2):304–308. [PubMed: 19170786]
40. Zadikoff C, Fox S, Tang-Wai D, et al. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. *Mov Disord.* 2008; 23(2):297–299. [PubMed: 18044697]
41. Alcalay R, Mejia-Santana H, Tang M, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. *J Clin Exp Neuropsychol.* 2010:1–5.

Table 1

Demographics of Study Population

	Mutation + (N=21)	Mutation – (N=21)
Gender (Female)	52.4%	52.4%
Age at PD onset mean (sd, min, max)	58.7 (9.7,43,74)	57.8 (8.7,41,72)
Age at testing - mean (sd, min, max)	65.7 (8.9,48,90)	66.4 (8.7,48,80)
Disease duration: years- mean (sd, min, max)	7.0 (5.4,1,19)	8.7 (4.3,2,19)
Highest level of education: high school, college, graduate	35%, 20%, 45%	15%, 35%, 50%
UPDRS-2 total- mean (sd)	6.4 (5.8)	8.1 (4.1)
UPDRS-3 total mean (sd)	9.5 (5.6)	11.2 (5.8)

Table 2

Summary of Behavioral and Cognitive Measures

	Mutation + <u>z score</u> [*]	Mutation – <u>z score</u>	Coefficient (95% CI)
HVLT-R Trial 1	–0.64	–0.47	–0.02 (–0.11 – 0.07)
HVLT-R Trial 2	–0.38	–0.47	0.02 (–0.05 – 0.09)
HVLT-R Trial 3	–0.30	–0.72	0.05 (–0.02 – 0.12)
HVLT-R delayed recall	–0.70	–0.85	0.02 (–0.05 – 0.90)
	<u>Mean Raw Score (s.d.)</u>	<u>Mean Raw Score (s.d.)</u>	
MMSE †	29.19 (1.40)	28.67 (1.91)	0.05 (–0.04 – 0.14)
JLO †	24.24 (4.81)	22.57 (5.66)	0.01 (–0.01 – 0.04)
FAB †	16.33 (2.52)	16.05 (2.11)	0.01 (–0.05 – 0.08)
BDI-2 †	10.57 (9.80)	7.81 (3.10)	0.01 (–0.01 – 0.03)
BAI †	11.14 (8.90)	7.44 (5.30)	0.02 (–0.01 – 0.04)

^{*} z score of < 1 s.d. below the normative data mean was considered significant

[†] cut-offs needed for significance: JLO: 19; FAB: 14; MMSE: 27, BDI-2 14, BAI 8

Table 3

Comparison of lifetime and premorbid prevalence of mood disorders in LRRK2 carriers and non-carriers

	Lifetime risk	Premorbid risk[*]
Any mood disorder	1.4 (0.44 – 4.41)	6.0 (0.72 – 49.84) ^{**}
Any major depressive disorder	2.0 (0.37 – 10.92)	4.0 (0.45 – 35.79)
Recurrent major depressive disorder	3.0 (0.31 – 28.84)	3.0 (0.31 – 28.84)
Time to any mood disorder	2.0 (0.68 – 5.85)	3.5 (0.73 – 16.85)
Time to any major depressive disorder	2.0 (0.37 – 10.92)	4.0 (0.45 – 35.79)
Time to recurrent major depressive disorder	3.0 (0.31 – 28.84)	3.0 (0.31 – 28.84)

^{*} Premorbid defined as onset at least five years prior to PD motor onset

^{**} p-value = 0.10

Table 4

Summary of results from important previous papers addressing the cognitive and/or psychiatric phenotype of LRRK2 PD

Authors	Sample	# LRRK2 G2019S cases analyzed	Cognitive measures	Behavioral measures	Authors' conclusions
Aasly et al. (2005)	Outpatient PD (n=435)	10	MMSE	descriptions only	Low prevalence of cognitive dysfunction and dementia among LRRK2 patients; psychiatric symptoms are mild
Lesage et al. (2005)	Autosomal Dominant Familial PD (198 probands)	21	MMSE	none	Lower MMSE scores in LRRK2 PD patients than in other autosomal dominant forms (n.s. after correcting for multiple testing)
Goldwurm et al. (2006)	Outpatient PD (n=1245)	17	MMSE, Clock drawing test, Rey Auditory Verbal Learning Test, Verbal fluency, Raven's Colored Progressive Matrices, FAB	NPI, HAM-D	Clinical features in carriers were those of typical IPD but behavioral abnormalities were frequent
Healy et al. (2008)	Outpatient PD (n=899)	313	MMSE	depression, anxiety, sleep disturbance (present, absent, not recorded)	Non-motor symptoms generally occurred at similar frequencies, but lower risk of cognitive impairment
Pankratz et al. (2008)	Familial PD, excluded if cognitive decline on MMSE or if on an antidepressant (n=840)	34	none (exclusion criterion)	GDS	No statistically significant difference by LRRK2 gene carrier status in depressive classification as measured by the GDS
Lohmann et al. (2008)	One large French Caucasian family (n=19)	12 unaffected carriers	MMSE, Mattis Dementia Rating Scale, FAB, Trails A/B	BDI	No differences in MMSE scores or BDI between unaffected LRRK2 carriers (n=12) and noncarriers (n=8)
Alcalay et al. (2010)	Early Onset PD (age at onset <51) prescreened as MMSE>23 (n=699)	20	MMSE, UPDRS I (item 1)	UPDRS Item 2 was covariate for cognitive analysis only	No difference in MMSE score between LRRK2 carriers and noncarriers in this sample of early onset PD prescreened for MMSE>23

Abbreviations: BDI: Beck Depression Inventory, FAB: Frontal Assessment Battery, GDS: Geriatric Depression Scale, HAM-D: Hamilton Rating Scale for Depression; IPD: idiopathic Parkinson's disease, MMSE: Mini-mental state examination, NPI: Neuropsychiatric Inventory, UPDRS: Unified Parkinson's Disease Rating Scale